PE20230105A1 - Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol - Google Patents

Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Info

Publication number
PE20230105A1
PE20230105A1 PE2022001894A PE2022001894A PE20230105A1 PE 20230105 A1 PE20230105 A1 PE 20230105A1 PE 2022001894 A PE2022001894 A PE 2022001894A PE 2022001894 A PE2022001894 A PE 2022001894A PE 20230105 A1 PE20230105 A1 PE 20230105A1
Authority
PE
Peru
Prior art keywords
tapentadol
dosage form
phosphoric acid
acid salt
form providing
Prior art date
Application number
PE2022001894A
Other languages
English (en)
Spanish (es)
Inventor
Ulrike Bertram
Ulrich Reinhold
Christian Grosse
Carmen Hartmann
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74701506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20230105(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20160419.6A external-priority patent/EP3875077B1/de
Priority claimed from EP20160420.4A external-priority patent/EP3875079A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20230105A1 publication Critical patent/PE20230105A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2022001894A 2020-03-02 2021-03-01 Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol PE20230105A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20160419.6A EP3875077B1 (de) 2020-03-02 2020-03-02 Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz
EP20160420.4A EP3875079A1 (de) 2020-03-02 2020-03-02 Darreichungsform mit verlängerter freisetzung von tapentadolphosphorsäuresalz
PCT/EP2021/055025 WO2021175773A1 (en) 2020-03-02 2021-03-01 Dosage form providing prolonged release of tapentadol phosphoric acid salt

Publications (1)

Publication Number Publication Date
PE20230105A1 true PE20230105A1 (es) 2023-01-25

Family

ID=74701506

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001894A PE20230105A1 (es) 2020-03-02 2021-03-01 Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Country Status (7)

Country Link
EP (1) EP4003318A1 (de)
BR (1) BR112022017700A2 (de)
CO (1) CO2022012567A2 (de)
DE (1) DE202021003994U1 (de)
MX (1) MX2022010780A (de)
PE (1) PE20230105A1 (de)
WO (1) WO2021175773A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230105A1 (es) 2020-03-02 2023-01-25 Gruenenthal Chemie Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
WO2006002886A1 (de) 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CA2667925A1 (en) 2006-10-27 2008-05-02 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
PE20190391A1 (es) 2008-10-30 2019-03-13 Gruenenthal Chemie Formas de dosificacion del tapentadol novedosas y potentes
WO2012010316A1 (en) 2010-07-23 2012-01-26 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP3027214A1 (de) 2013-08-02 2016-06-08 ratiopharm GmbH Zusammensetzung mit tapentadol in gelöster form
EP2942054A1 (de) 2014-05-09 2015-11-11 G.L. Pharma GmbH Pharmazeutische Formulierung mit langsamer Wirkstoffabgabe
DK3445742T3 (da) 2016-04-19 2020-02-24 Ratiopharm Gmbh Krystallin tapentadolphosphat
WO2018219897A1 (en) 2017-05-29 2018-12-06 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
PE20230105A1 (es) 2020-03-02 2023-01-25 Gruenenthal Chemie Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol

Also Published As

Publication number Publication date
EP4003318A1 (de) 2022-06-01
DE202021003994U1 (de) 2022-04-12
WO2021175773A1 (en) 2021-09-10
BR112022017700A2 (pt) 2023-01-17
CO2022012567A2 (es) 2022-09-09
MX2022010780A (es) 2022-09-26

Similar Documents

Publication Publication Date Title
ES2482104T3 (es) Formulaciones HRT
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
KR20230145525A (ko) 과다 졸림증을 치료하기 위한 방법 및 조성물
AR059723A2 (es) Composicion de altas dosis de ibandronato
CO5410187A1 (es) Formulacion oral de dosis unica de espinosad
PE20230105A1 (es) Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol
US11925612B2 (en) Bactericidal and virucidal pharmaceutical composition
AR033671A1 (es) Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento
ES2349996T3 (es) Preparado de liberación retardada en forma de pellas que contiene cinarizina y dimenhidrinato contra el vértigo.
BR112024001927A2 (pt) Formas de dosagem gastrorretentivas de 5-hidroxitriptofano
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
RU2006137329A (ru) Распадающиеся таблетки, содержащие ликарбазепин
ES2923673T3 (es) Comprimido vaginal mucoadhesivo de liberación prolongada
KR101531030B1 (ko) 미르타자핀 함유 구강붕해정
CN110833540B (zh) 一种柳酚咖敏片及其制备方法
PE20221446A1 (es) Nuevas formulaciones de comprimido de fosfomicina
CN103301063A (zh) S（+）-氟比洛芬酯注射乳剂
PE20240113A1 (es) Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico
AR129775A1 (es) Composición farmacéutica que contiene agonista del receptor de adenosina a3 para el tratamiento de la psoriasis
ES2211374T1 (es) Dosificacion metronomica de taxanos para inhibir el crecimiento tumoral.
PE20220381A1 (es) Formulacion de tableta vaginal
RU2617238C1 (ru) Способ получения лекарственного средства с кислотой янтарной и цетилпиридиний хлоридом местного действия
WO2018138652A1 (es) Composición farmacéutica de loratadina, fenilefrina, paracetamol y amantadina para su administracion oral, para el tratamiento de alopatías relacionadas a un resfriado comun
PT117658A (pt) Processo de preparação de formulação terapêutica, formulação terapêutica, composição farmacêutica, dispositivo médico e utilização da formulação terapêutica como medicamento à base de solventes eutécticos profundos e de princípios ativos
TWD207945S (zh) 藥物輸送裝置